Orthocell (ASX:OCC) has appointed Device Technologies Asia (DT Asia) as the exclusive distributor for its neurorepair device Remplir in Singapore. This will be the product’s first major international expansion beyond Australia and New Zealand, where sales have grown significantly.

Orthocell is a regenerative medicine company focused on repairing bone and soft tissue injuries.

Remplir, a key product in the company’s portfolio, is a collagen nerve wrap used for peripheral nerve repair. It protects the nerves without compressing them and creates an ideal microenvironment that helps the nerves heal. Because the device is absorbable, it safely dissolves over time as the nerve regenerates, eliminating the need for surgical removal. This approach distinguishes itself from traditional methods and reduces surgical complexity, recovery time, and patient discomfort.

The distribution agreement follows Remplir’s recent regulatory approval in Singapore, with first market availability expected by Q1 2025. Singapore has a reputation for advanced medical care and regulatory influence, and is considered a strategic entry point into the ASEAN region. Orthocell estimates that the global neurorepair market is worth more than US$3.5 billion.

Paul Anderson, Chief Executive Officer of Orthocell, commented: “Device Technologies Asia has a proven track record of successfully launching high-quality medical products. We are pleased to extend our partnership to Singapore and look forward to driving adoption of Remplir in this key market. .”

The company is on track to submit an application for Remplir to the U.S. Food and Drug Administration by the end of 2024.

The stock is trading 9.38% higher at 70 cents.